EN DE

Polarean Imaging plc (PLLWF) Fair Value & Analysis

Healthcare · US · Market cap $8.0M

PI Polarean Imaging plc logo Polarean Imaging plc PLLWF · US
Price$0.0066
Fair Value$0.0058
Upside-12.1%
Quality41/100
Watch Polarean Imaging plc for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Thin margins · 0.0% net margin
negative free cash flow
Trails peers (2/8)
Narrow moat 8/100
Evidence: Low Range $0.0058 – $0.0058 Share as image

Fair value as of: Jul 31, 2026

From 1 valuation models · updated 10 days ago

Below-average quality, and screening another 12% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case ($0.0058). The favourable scenario is already priced in.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

$1.50 $0.0010 Fair Value $0.0058 Apr 2021 Jul 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 31, 2026.

How to read this chart

60‑month range $0.0010 – $1.50 · the $0.0066 price screens above the $0.0058 fair value. Dashed = 300-day average. As of Jul 31, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Polarean Imaging plc (PLLWF) currently trades at $0.0066, while our model-based Fair Value estimate is $0.0058, implying the stock looks roughly 12.1% overvalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at $2.6M. Revenue declined 46.9% year over year. It earns a return on equity of -81.0%. The balance sheet holds a net cash position of $11.6M. Fundamentals as of Jul 31, 2026

The share trades about 40% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -12%, PLLWF screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
NCAV (Graham) $0.0100 $0.0100 $0.0100 50
All 1 models by family
Asset-Based
NCAV (Graham) $0.0100 $0.0100 $0.0100 50

Notify me when PLLWF reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) $2.6M
Revenue growth (YoY) -46.9%
Return on equity -81.0%
Free cash flow −$5.8M FY2024
Operating margin -889%
Net cash $11.6M FY2024

Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 41/100

Of which business quality 41 · Market factors (momentum, volatility) 35

Profitability 4
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 4
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 92
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 29
Price trend over the last 3–12 months (market factor)
52W Momentum 28
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States. The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform.

Full company description

Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States. The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. It also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; chest coil; Polarean 9820 Xenon hyperpolarizer that is designed to deliver up to 3 litres of hyperpolarized 129Xe per hour; and Polarean 2881 polarization measurement station, which provides a calibrated measurement of the polarization of hyperpolarized gas within the dose delivery inhalation bag. Polarean Imaging plc was incorporated in 2016 and is based in London, the United Kingdom.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2020 – FY2024 · reported fiscal years

Polarean Imaging plc reported revenue of $3.1M in FY2024 versus $1.1M in FY2020, a compound +30.8%/yr. Reported net income was −$8.5M in FY2024.

Growth Quality 17/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2024)
$3.1M
Latest YoY
+246.8%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+37.6%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+6.1%
Avg. growth/yr (10Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+12.3%
Revenue +30.8%/yr
FY20 $1.1M
FY21 $1.2M
FY22 $1.0M
FY23 $891K
FY24 $3.1M
Net income
FY20 −$6.5M
FY21 −$14.0M
FY22 −$13.9M
FY23 −$11.9M
FY24 −$8.5M

PLLWF screens 12% overvalued. Compare with Abbott Laboratories, →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Polarean Imaging plc Fair Value". https://www.fairvalue-calculator.com/stock/PLLWF

Peer Group

Medical Devices · 352 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 41 · Below median
Fair Value upside −12% · Above median
Return on assets -42% · Bottom 25%
Net margin (TTM) 0% · Below median
Revenue growth -47% · Bottom 25%

Valuation Multiples vs Medical Devices median · lower = cheaper

P/B 0.66× · Cheaper than median
P/S (TTM) 3.11× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 17 · sector 0
FUTURE 0 · sector 29
PAST 0 · sector 8
HEALTH 0 · sector 97
DIVIDEND 0 · sector 38

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $100.68 $74.79 -26%
Stryker Corporation SYK $316.44 $186.28 -41%
Medtronic plc MDT $83.56 $65.57 -22%
Boston Scientific Corporation BSX $43.04 $38.44 -11%
Edwards Lifesciences Corporation EW $85.73 $41.02 -52%
Siemens Healthineers AG SHL €34.59 €33.87 -2%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥149.43 ¥147.63 -1%
Shanghai United Imaging Healthcare Co 688271 ¥109.00 ¥43.60 -60%
Demant A/S DEMANT kr 276.60 kr 161.17 -42%
Getinge AB GETIB kr 206.80 kr 192.14 -7%

Compare Polarean Imaging plc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Polarean Imaging plc (PLLWF) overvalued or undervalued?
As of Jul 31, 2026, our model estimates a fair value of $0.0058 versus a price of $0.0066, about −12% (overvalued).
What is the fair value of PLLWF?
Our model-based fair value for Polarean Imaging plc is $0.0058 (as of Jul 31, 2026), built from audited fundamentals. The current price is $0.0066.
What is the quality score of PLLWF?
Polarean Imaging plc has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Polarean Imaging plc (PLLWF)?
Polarean Imaging plc reported trailing-twelve-month revenue of about $2.6M (latest available figure, as of Jul 31, 2026).
What is the net profit margin of PLLWF?
The net profit margin of Polarean Imaging plc is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Polarean Imaging plc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.